Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Stoboclo, Osenvelt. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Denosumab-Bmwo (sold as Stoboclo, Osenvelt), first approved Oct 29, 2025, with 0 new uses approved and 0 published complete response letters.
First approved: Oct 29, 2025
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $15.3M
First approved in the EU: May 26, 2010
First approved in Japan: Jan 18, 2012
Safety program: REMS
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
OSENVELT
Part B
$13.7M
New
4,891
Osenvelt
Part D
$1.4M
New
158
Stoboclo
Part D
$258K
New
154
Where Medicare Prescribes It
468,320 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Hawaii 8.9×, California 1.9×, New York 1.9×
Least
Minnesota 0.1×, Wisconsin 0.1×, Iowa 0.2×
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
STOBOCLO 60 MG/ML SYRINGE: $1578.10 per MLBrand · new this year
FDA Drug Safety Communications
One communication since 2020 that name this drug; see all communications
First approved in Japan 165 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
ProliaA drug with a new additional indication and a new dosage indicated for inhibiting progression of bone erosion associated with rheumatoid arthritis. · Daiichi Sankyo Company, Limited · Jul 3, 2017
RanmarkA drug with a new additional indication and a new dosage for the treatment of giant cell tumor of bone. · Daiichi Sankyo Company, Limited · May 23, 2014
Pralia, new approvalA drug with a new indication and a new dosage for the treatment of osteoporosis. · Daiichi Sankyo Company, Limited · Mar 25, 2013
Ranmark, new ingredientA drug with a new active ingredient indicated for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor. · Daiichi Sankyo Company, Limited · Jan 18, 2012
Safety Programs (REMS)
FDA requires these when a drug's risks need more than a label: training, enrollment or extra checks before it is prescribed or dispensed
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA